# To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study

> **NCT01096017** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Terbutaline Turbuhaler®
- **DRUG:** Salbutamol pMDI
- **OTHER:** pMDI placebo pMDI
- **OTHER:** Placebo Turbuhaler®

## Key facts

- **NCT ID:** NCT01096017
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01096017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01096017, "To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01096017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*